Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of the Safety and Efficacy of an Oral Formulation of SPI-1005 for Prevention of Temporary Auditory Threshold Shift

NCT01444846 is registered in ClinicalTrials.gov with Sound Pharmaceuticals, Incorporated as lead sponsor.

NCT NCT01444846
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01444846 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of the Safety and Efficacy of an Oral Formulation of SPI-1005 for Prevention of Temporary Auditory Threshold Shift
Lead sponsor
Sound Pharmaceuticals, Incorporated
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2011
Completion date
March 31, 2014
Enrollment
83 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

temporary auditory threshold shift